Articles From: French Toast Crunch Cereal Makes Slammin' Return to Karyopharm Presents Positive Combination Data for Selinexor (KPT-330) in Multiple Myeloma Patients at ASH 2014 Annual Meeting


2014/12/8
Fans Inspire the Revival of the 1990's Favorite MINNEAPOLIS , Dec.
Sign-up for French Toast Crunch Cereal Makes Slammin' Return investment picks
2014/12/8
By Ned Levin HONG KONG--The bribery trial of two billionaire brothers and Hong Kong's former No.
Sign-up for Protests Overshadow Hong Kong Moguls' Trial investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163621&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for CBD Energy Announces Receipt of Notice of Delisting by NASDAQ investment picks
2014/12/8
Discover’s website has received the top overall score for customer experience in a recent study performed by Keynote.
Sign-up for Keynote Ranks Discover Website #1 in Q4 2014 Credit Card Scorecard Study investment picks
95% (19/20) Overall Response Rate (ORR) in Patients with High-Risk CLL, the patient population to be studied in recently announced Phase 3 Clinical Trial being conducted under Special Protocol Assessment (SPA) 87% (34/39) ORR per iwCLL criteria in all evaluable CLL patients plus an additional 10% of patients with a nodal PR or nodal reductions ranging from 20%-45% without disease progression 88% (7/8) ORR in all evaluable Mantle Cell Lymphoma (MCL) patients with a 38% (3/8) Complete Response rate Combination of TG-1101 + Ibrutinib well tolerated with limited Grade 3/4 events reported to date SAN FRANCISCO, Dec.
Sign-up for Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) investment picks
2014/12/8
The path to a cleaner, region-wide energy future will become clearer when two experienced organizations in the regional energy market announce Tuesday the joining of forces to deliver a unique blend of renewable energy to New England.
Sign-up for New Alliance Created to Deliver Clean, Reliable Energy to New England investment picks
2014/12/8
Levi & Korsinsky is investigating the Board of Directors of Hawaiian Electric Industries, Inc. (“Hawaiian Electric” or “the Company”) (NYSE: HE) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to NextEra Energy Inc. (NYSE: NEE). Click here to learn more about the investigation : http://www.zlkdocs.com/HE-Info-Request-Form_ma-2420 .
Sign-up for SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Hawaiian Electric Industries, Inc. Regarding the Fairness of the Sale of the Company to NextEra Energy Inc. investment picks
CIBC Asset Management completes fund merger Canada NewsWire TORONTO , Dec.
Sign-up for CIBC Asset Management completes fund merger investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis (apixaban) by 4-factor prothrombin complex concentrates (PCCs) in healthy subjects.
Sign-up for Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects investment picks
2014/12/8
http://media.marketwire.com/attachments/201412/82488_echogen.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163641&ProfileId=051205&sourceType=1 ORLANDO, FL --
Sign-up for Echogen Power Systems' Waste Heat Recovery System Available as Turnkey Solution investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company’s Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT). Epizyme, along with its partner Celgene, is developing EPZ-5676 for the treatment of acute leukemia with alterations in the MLL gene (MLL-r) or partial tandem duplications within MLL (MLL-PTD). The trial found that EPZ-5676 was generally safe and well tolerated across all dose cohorts and showed clinical and biological activity.
Sign-up for Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical and Biological Activity in Adult Patients with Acute Leukemias in Phase 1 Trial investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL). PRMT5 is an arginine methyltransferase (RMT), a subset of histone methyltransferases (HMTs), that is overexpressed in multiple human malignancies, including MCL.
Sign-up for Epizyme First-in-Class PRMT5 Inhibitor Demonstrates In Vitro and In Vivo Activity in Models of Mantle Cell Lymphoma investment picks
2014/12/8
The top 20 TV series on Xfinity On Demand for the week of November 23 – November 29 were: 1.
Sign-up for Xfinity On Demand Top 20 TV Shows for the Week of November 23 – November 29 investment picks
2014/12/8
By Yvonne Lee And Prudence Ho A year-end revival in Hong Kong's IPO market has brought what could be the world's biggest property-stock listing to the city.
Sign-up for Dalian Wanda Is Raising Up To $3.8 Billion at Discount investment picks
2014/12/8
This year’s festive season gift list will feature more products invented by startups than ever.
Sign-up for This Year’s Gift Could Turn You Into Next Year’s Tech Star investment picks
Levi & Korsinsky is investigating the Board of Directors of Spansion, Inc. (“Spansion” or “the Company”) (NYSE: CODE) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Cypress Semiconductor Corporation (“Cypress”) (NasdaqGS: CY). Click here to learn more about the investigation: http://zlk.9nl.com/spansion-code .
Sign-up for INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Spansion, Inc. Regarding the Fairness of the Sale of the Company to Cypress Semiconductor Corp. -- CODE investment picks
Boutique hotel brand celebrates U.S. debut in historic Cotton Exchange building in New Orleans NEW ORLEANS , Dec.
Sign-up for AC Hotels by Marriott Imports European Sophistication To North America investment picks
Former United States Securities and Exchange Commission attorney Willie Briscoe , founder of The Briscoe Law Firm, PLLC , and the securities litigation firm of Powers Taylor LLP announce that a class action lawsuit has been filed against Rayonier, Inc. (“Rayonier” or “Company”) (NYSE: RYN) and several officers and directors for acts taken during the period of April 29, 2014 to November 10, 2014 (the “Class Period”). Based upon the allegations in the class action, the firms are investigating additional legal claims against the officers and Board of Directors of Rayonier.
Sign-up for Rayonier, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors investment picks
Keysight Technologies, Inc. (NYSE:KEYS) today announced that Frost & Sullivan has recognized Keysight with the 2014 Global Frost & Sullivan Award for Market Leadership in Instrumentation Software for excellence in capturing the highest market revenue within its industry.
Sign-up for TRADE NEWS: Keysight Technologies Receives 2014 Global Frost & Sullivan Award for Market Leadership in Instrumentation Software investment picks
- Selinexor Demonstrates Synergy in Combination with Approved Therapies for Multiple Myeloma - NEWTON, Mass., Dec.
Sign-up for Karyopharm Presents Positive Combination Data for Selinexor (KPT-330) in Multiple Myeloma Patients at ASH 2014 Annual Meeting investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: French Toast Crunch Cereal Makes Slammin' Return to Karyopharm Presents Positive Combination Data for Selinexor (KPT-330) in Multiple Myeloma Patients at ASH 2014 Annual Meeting
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent